Kaye SB - Search Results

1

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

Dolly SO, Migali C, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, de Bono JS, Kaye SB, Banerjee S. Dolly SO, et al. Among authors: kaye sb. ESMO Open. 2017 Apr 12;2(1):e000101. doi: 10.1136/esmoopen-2016-000101. eCollection 2017. ESMO Open. 2017. PMID: 28761723 Free PMC article.

2

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.

Banerjee S, Kaye SB. Banerjee S, et al. Among authors: kaye sb. Clin Cancer Res. 2013 Mar 1;19(5):961-8. doi: 10.1158/1078-0432.CCR-12-2243. Epub 2013 Jan 10. Clin Cancer Res. 2013. PMID: 23307860 Review.

3

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Rafii S, et al. Among authors: kaye sb. Clin Cancer Res. 2015 Apr 15;21(8):1869-76. doi: 10.1158/1078-0432.CCR-14-2424. Epub 2015 Feb 3. Clin Cancer Res. 2015. PMID: 25649020 Free PMC article.

4

New developments in the treatment of ovarian cancer--future perspectives.

Lopez J, Banerjee S, Kaye SB. Lopez J, et al. Among authors: kaye sb. Ann Oncol. 2013 Dec;24 Suppl 10(Suppl 10):x69-x76. doi: 10.1093/annonc/mdt475. Ann Oncol. 2013. PMID: 24265409 Free PMC article. Review.

5

Revisiting the role of antiandrogen strategies in ovarian cancer.

Papadatos-Pastos D, Dedes KJ, de Bono JS, Kaye SB. Papadatos-Pastos D, et al. Among authors: kaye sb. Oncologist. 2011;16(10):1413-21. doi: 10.1634/theoncologist.2011-0164. Epub 2011 Sep 23. Oncologist. 2011. PMID: 21948654 Free PMC article. Review.

6

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.

Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U. Geuna E, et al. Among authors: kaye sb. Br J Cancer. 2015 Dec 1;113(11):1541-7. doi: 10.1038/bjc.2015.373. Epub 2015 Nov 10. Br J Cancer. 2015. PMID: 26554652 Free PMC article.

7

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

Tunariu N, Kaye SB, Desouza NM. Tunariu N, et al. Among authors: kaye sb. Br J Cancer. 2012 Feb 14;106(4):619-28. doi: 10.1038/bjc.2011.579. Epub 2012 Jan 26. Br J Cancer. 2012. PMID: 22281664 Free PMC article. Review.

8

From darkness to light with biomarkers in early clinical trials of cancer drugs.

Carden CP, Banerji U, Kaye SB, Workman P, de Bono JS. Carden CP, et al. Among authors: kaye sb. Clin Pharmacol Ther. 2009 Feb;85(2):131-3. doi: 10.1038/clpt.2008.223. Clin Pharmacol Ther. 2009. PMID: 19151637 Review.

9

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J. Sundar R, et al. Among authors: kaye sb. Clin Oncol (R Coll Radiol). 2018 Mar;30(3):185-191. doi: 10.1016/j.clon.2017.11.011. Epub 2017 Dec 7. Clin Oncol (R Coll Radiol). 2018. PMID: 29224898 Free article.

10

A decade of clinical development of PARP inhibitors in perspective.

Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Among authors: kaye sb. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

735 results

Search Page